Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1132-1140

  Safarinejad, Mohammad Reza ^a   Safarinejad, Shiva ^a   Shafiei, Nayyer ^a   Safarinejad, Saba ^a  

^a Clinical center for urological disease diagnosis   (Iran)

Author keywords

Cancer; ENOS; Genetics; Nitric oxide; Polymorphism; Prostate

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ADULT; ADVANCED CANCER; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT;

CANCER; ENOS; GENETICS; NITRIC OXIDE; POLYMORPHISM; PROSTATE;

AGED; ALLELES; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INTRONS; LOGISTIC MODELS; MALE; MIDDLE AGED; MINISATELLITE REPEATS; MULTIVARIATE ANALYSIS; NITRIC OXIDE SYNTHASE TYPE III; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84884675035     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.01.002     Document Type: Article

References (32)

1. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-142.
2. Stuehr D.J. Mammalian nitric oxide synthases. Biochim Biophys Acta 1999, 1411:217-230.
3. Karashima T., Taguchi T., Yoshikawa C., et al. Numerical chromosomal changes in metastatic prostate cancer following anti-androgen therapy: Fluorescence in situ hybridization analysis of five Japonese cases. Cancer Genet Cytogenet 2000, 20:148-154.
4. Nihei N., Ohta S., Kuramochi H., et al. Metastasis suppressor gene(s) for rat prostate cancer on the long arm of human chromosome7. Genes Chromosome Cancer 1999, 24:1-8.
5. Marsden P.A., Heng H.H., Scherer S.W., et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993, 268:17478-17488.
6. Wang X.L., Mahaney M.C., Sim A.S., et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler Thromb Vasc Biol 1997, 17:3147-3153.
7. Nakayama M., Yasue H., Yoshimura M., et al. T-786→C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999, 99:2864-2870.
8. Nakayama M., Yoshimura M., Sakamoto T., et al. A-786T NC polymorphism in the endothelial nitric oxide synthase gene reduces serum nitrite/nitrate levels from the heart due to an intracoronary injection of acetylcholine. Pharmacogenet Genomics 2006, 16:339-345.
9. Klotz T., Bloch W., Volberg C., et al. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 1998, 82:1897-1903.
10. Thomsen L.L., Miles D.W., Happerfield L., et al. Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995, 72:41-44.
11. Babaei S., Teichert-Kuliszewska K., Zhang Q., et al. Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am J Pathol 2003, 162:1927-1936.
12. Li L.M., Kilbourn R.G., Adams J., et al. Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res 1991, 51:2531-2535.
13. Kong L., Dunn G.D., Keefer L.K., et al. Nitric oxide reduces tumor cell adhesion to isolated rat postcapillary venules. Clin Exp Metastasis 1996, 14:335-343.
14. Yoshie Y., Ohshima H. Synergistic induction of DNA strand breakage by catechol-estrogen and nitric oxide: Implications for hormonal carcinogenesis. Free Radic Biol Med 1998, 24:341-348.
15. Calmels S., Hainaut P., Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res 1997, 57:3365-3369.
16. Sugano M., Tsuchida K., Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Biochem Biophys Res Commun 2000, 272:872-876.
17. Polte T., Oberle S., Schroder H. Nitric oxide protects endothelial cells from tumor necrosis factor a-mediated cytotoxicity: Possible involvement of cyclic GMP. FEBS Lett 1997, 409:46-48.
18. Sanli O., Kucukgergin C., Gokpinar M., et al. Despite the lack of association between different genotypes and the presence of prostate cancer, endothelial nitric oxide synthase a/b (eNOS4a/b) polymorphism may be associated with advanced clinical stage and bone metastasis. Urol Oncol 2011, 29:183-188.
19. Medeiros R., Morais A., Vasconcelos A., et al. Endothelial nitric oxide synthase gene polymorphisms and the shedding of circulating tumor cells in the blood of prostate cancer patients. Cancer Lett 2003, 189:85-90.
20. Marangoni K., Neves A.F., Cardoso A.M., et al. The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Cancer Detect Prev 2006, 30:7-13.
21. Medeiros R.M., Morais A., Vasconcelos A., et al. Outcome in prostate cancer: Association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res 2002, 8:3433-3437.
22. Safarinejad M.R., Shafiei N., Safarinejad S. The role of endothelial nitric oxide synthase (eNOS) T-786C, G894T, and 4a/b gene polymorphisms in the risk of idiopathic male infertility. Mol Reprod Dev 2010, 77:720-727.
23. Marroni A.S., Metzger I.F., Souza-Costa D.C., et al. Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase (eNOS) genetic polymorphisms. Nitric Oxide 2005, 12:177-182.
24. Tanus-Santos J.E., Desai M., Deak L.R., et al. Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 2002, 12:407-413.
25. Lewontin R.C. On measures of gametic disequilibrium. Genetics 1988, 120:849-852.
26. Medeiros R., Morais A., Vasconcelos A., et al. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev 2002, 11:343-350.
27. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993, 329:2002-2012.
28. Schwartsburd P.M. Chronic inflammation as inductor of pro-cancer microenvironment: Pathogenesis of dysregulated feedback control. Cancer Metastasis Rev 2003, 22:95-102.
29. Wang X.L., Sim A.S., Wang M.X., et al. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett 2000, 471:45-50.
30. Wang Y.Z., Cao Y.Q., Wu J.N., et al. Expression of nitric oxide synthase in human gastric carcinoma and its relation to p53, PCNA. World J Gatroenterol 2005, 11:46-50.
31. Jadeski L.C., Chakraborty C., Lala P.K. Role of nitric oxide in tumor progression with special reference to a murine breast cancer model. Can J Physiol Pharmacol 2002, 8:125-135.
32. Sonveaux P., Jordan B.F., Gallez B., et al. Nitric oxide delivery to cancer: Why and how?. Eur J Cancer 2009, 45:1352-1369.